AI Summary
- Ongoing research required to develop paediatric-specific treatments and high quality evidence for paroxysmal sympathetic hyperactivity management.
- Current therapies are limited and heterogeneous, emphasising need for standardised protocols and clinical trials in children.
- Early recognition, multidisciplinary care and long term follow up improve outcomes and guide treatment development.
Hosp Pediatr. 2026 Nov 16:e2026009869. doi: 10.1542/hpeds.2026-009869. Online ahead of print.
NO ABSTRACT
PMID:43035108 | DOI:10.1542/hpeds.2026-009869
Share Evidence Blueprint
Save to Google Notes

Search Google Scholar
⭐ My Revision List

